Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibAdam J. Schoenfeld, Matthew D. Hellmann, Kathryn C. Arbour et al.|Annals of Oncology|2019Cited by 413
COVID-19 in patients with lung cancerJie Luo, Matthew D. Hellmann, Adam J. Schoenfeld et al.|Annals of Oncology|2020Cited by 269
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) BlockadeJuan C. Osorio, Matthew D. Hellmann, Kathryn C. Arbour et al.|Journal of Clinical Oncology|2019Cited by 134
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D. Hellmann, Maximilian Diehn, Barzin Y. Nabet et al.|Clinical Cancer Research|2020Cited by 123
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerBiagio Ricciuti, Jia Luo, Joao V. Alessi et al.|Annals of Oncology|2022Cited by 100